Status:
TERMINATED
Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Diabetic Macular Edema
Eligibility:
All Genders
18-85 years
Phase:
PHASE2
Brief Summary
To assess the efficacy of oral aliskiren as a therapy for diabetic macular edema
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Type 1 or type 2 diabetes
- Diabetic macular edema
- Exclusion criteria:
- Recent intra-ocular surgery in the study eye (e.g., cataract surgery in the last 6 months)
- Recent laser photocoagulation in the study eye
- Recent treatment with Avastin, Lucentis, or intravitreal corticosteroids in the study eye
- Other protocol-defined inclusion/exclusion criteria applied
Exclusion
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2011
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00768040
Start Date
September 1 2008
End Date
February 1 2011
Last Update
March 6 2012
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Retinal Consultants of Arizona
Phoenix, Arizona, United States
2
Retina-Vitreous Associates
Los Angeles, California, United States
3
National Ophthalmic Research Institute
Fort Myers, Florida, United States
4
Georgia Retina
Atlanta, Georgia, United States